Development and Validation of a Novel Bleeding Risk Prediction Tool for Aspirin Users with a Low Body Mass Index

Overview

Journal Sci Rep

Date 2025 Feb 7

PMID 39920211

Authors

Lu Yifang

Lei Wanlin

Wang Maofeng

Affiliations

Soon will be listed here.

Abstract

Aspirin is commonly utilized in the management and prevention of various diseases. However, in specific individuals, particularly those with low body mass index (BMI), aspirin can elevate the risk of bleeding. Achieving a delicate equilibrium between the desirable antiplatelet effects and potential bleeding complications is a notable consideration. The objective of this study was to create a novel bleeding risk prediction tool for aspirin users with a low BMI. A total of 2436 aspirin users with a low BMI were included in this study conducted at the Affiliated Dongyang Hospital of Wenzhou Medical University. Patient data, comprising demographics, clinical characteristics, comorbidities, medical history, and laboratory tests, were collected. The patients were randomly divided into two groups, with a 7:3 ratio, for model development and internal validation purposes. The identification of clinically significant features associated with bleeding was achieved through the utilization of the Least Absolute Shrinkage and Selection Operator (LASSO) regression and boruta analysis. Subsequently, these important features underwent multivariate logistic regression analysis. Based on independent bleeding risk factors, a logistic regression model was constructed and presented as a nomogram. Model performance was evaluated using metrics such as the area under the curve (AUC), calibration curves, decision curve analysis (DCA), clinical impact curve (CIC), and net reduction curve (NRC) in both the training and testing sets. LASSO analysis identified two clinical features, while Boruta analysis identified nine clinical features out of a total of 21 features. Subsequent multivariate logistic regression analysis selected significant independent risk factors. The boruta model, which demonstrated the highest AUC, consisted of six clinical variables: hemoglobin, platelet count, previous bleeding, tumor, smoke, and diabetes mellitus. These variables were integrated into a visually represented nomogram. The model exhibited an AUC of 0.832 (95% CI: 0.788-0.875) in the training dataset and 0.775 (95% CI: 0.698-0.853) in the test dataset, indicating excellent discriminatory performance. Calibration curve analysis revealed close alignment with the ideal curve. Furthermore, DCA, CIC, and NRC demonstrated favorable clinical net benefit for the model. This study has successfully created a novel risk prediction tool specifically designed for aspirin users with a low BMI. This tool enables the stratification of low BMI patients based on their anticipated bleeding risk.

References

Jatis A, Nei S, Zieminski J, Mara K, Krauter A . Assessment of bleeding risk in low-weight patients receiving prophylactic subcutaneous unfractionated heparin. Vasc Med. 2023; 28(5):443-448. DOI: 10.1177/1358863X231189758. View

Landi A, Alasnag M, Heg D, Frigoli E, Malik F, Gomez-Blazquez I . Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2023; 9(1):35-44. PMC: 10666042. DOI: 10.1001/jamacardio.2023.4316. View

Premji A, Blegen M, Corley A, Ulloa J, Booth M, Begashaw M . Dual antiplatelet management in the perioperative period: updated and expanded systematic review. Syst Rev. 2023; 12(1):197. PMC: 10576385. DOI: 10.1186/s13643-023-02360-9. View

Huang J, Liao F, Tang J, Shu X . Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy. Clin Neurol Neurosurg. 2023; 231:107802. DOI: 10.1016/j.clineuro.2023.107802. View

Mihatov N, Kirtane A, Stoler R, Feldman R, Neumann F, Boutis L . Bleeding and Ischemic Risk Prediction in Patients With High Bleeding Risk (an EVOLVE Short DAPT Analysis). Am J Cardiol. 2023; 207:370-379. DOI: 10.1016/j.amjcard.2023.06.036. View

Chilbert M, Reidy S, Clark C, Guszkowski M, Gargala E, Woodruff A . Comparison of Bleeding Rates between Oral Anticoagulants in Combination with Dual Antiplatelet Therapy (Triple Therapy) in a Real-World Cohort. Hosp Pharm. 2022; 57(2):253-259. PMC: 9117778. DOI: 10.1177/00185787211024602. View

Levi M . Disseminated Intravascular Coagulation in Cancer: An Update. Semin Thromb Hemost. 2019; 45(4):342-347. DOI: 10.1055/s-0039-1687890. View

Kadiyala V, Long S, Has P, Lima F, Sherrod 4th C, Heinl R . PRECISE-DAPT and ARC-HBR Predict in-Hospital Outcomes in Patients Who Underwent Percutaneous Coronary Intervention. Am J Cardiol. 2023; 191:43-50. DOI: 10.1016/j.amjcard.2022.12.004. View

Won K, Shin E, Kang J, Yang H, Park K, Han K . Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents　- Results From the HOST-EXAM Trial. Circ J. 2022; 87(2):268-276. DOI: 10.1253/circj.CJ-22-0344. View

10.

Croft D, Cameron S, Morrell C, Lowenstein C, Ling F, Zareba W . Associations between ambient wood smoke and other particulate pollutants and biomarkers of systemic inflammation, coagulation and thrombosis in cardiac patients. Environ Res. 2017; 154:352-361. PMC: 5375102. DOI: 10.1016/j.envres.2017.01.027. View

11.

Capodanno D, Rossini R, Musumeci G, Lettieri C, Senni M, Valsecchi O . Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Int J Cardiol. 2015; 199:319-25. DOI: 10.1016/j.ijcard.2015.07.064. View

12.

Sim D, Jeong M, Kim H, Gwon H, Seung K, Rha S . Utility of GRACE and ACUITY-HORIZONS risk scores to guide dual antiplatelet therapy in Korean patients with acute myocardial infarction undergoing drug-eluting stenting. J Cardiol. 2018; 72(5):411-419. DOI: 10.1016/j.jjcc.2018.04.006. View

13.

Jones W, Mulder H, Wruck L, Pencina M, Kripalani S, Munoz D . Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021; 384(21):1981-1990. PMC: 9908069. DOI: 10.1056/NEJMoa2102137. View

14.

Morici N, Tavecchia G, Antolini L, Caporale M, Cantoni S, Bertuccio P . Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With Acute Coronary Syndrome. Angiology. 2019; 70(9):867-877. DOI: 10.1177/0003319719848547. View

15.

Liang C, Wanling L, Maofeng W . LASSO-derived model for the prediction of bleeding in aspirin users. Sci Rep. 2024; 14(1):12507. PMC: 11143346. DOI: 10.1038/s41598-024-63437-6. View

16.

Lynch D, Howard A, Tien H, Du S, Zhang B, Wang H . Association Between Weight Status and Rate of Cognitive Decline: China Health and Nutrition Survey 1997-2018. J Gerontol A Biol Sci Med Sci. 2023; 78(6):958-965. PMC: 10235196. DOI: 10.1093/gerona/glad051. View

17.

Lambert C, Maitland H, Ghanima W . Risk-based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP). Eur J Haematol. 2023; 112(4):504-515. DOI: 10.1111/ejh.14154. View

18.

Alzahrani S, Ajjan R . Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010; 7(4):260-73. DOI: 10.1177/1479164110383723. View

19.

Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F . Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017; 389(10073):1025-1034. DOI: 10.1016/S0140-6736(17)30397-5. View

20.

DeFilippis A, Young R, Carrubba C, McEvoy J, Budoff M, Blumenthal R . An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015; 162(4):266-75. PMC: 4414494. DOI: 10.7326/M14-1281. View